Close

Aptose Biosciences (APTO) Updates on APTO-253 FDA Clinical Hold; Says Additional Info Requested Before Removed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. IBM
4. HCP
5. BSX
6. LRCX
7. BIIB
8. PI
9. NOW
10. ALGN


Go back to Aptose Biosciences (APTO) Updates on APTO-253 FDA Clinical Hold; Says Additional Info Requested Before Removed

Roth Capital Affirms Aptose Biosciences (APTO) at 'Buy'; Clinical Hold Update Disappointing, But Positives Remain

October 13, 2016 11:53 AM EDT

Roth capital affirms Aptose Biosciences (Nasdaq: APTO) at Buy with a price target of $8 after the company announced that it received a response from the U.S.... More